ARVN Stock Summary and Trading Ideas (Arvinas | NASDAQ:ARVN)

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Arvinas trades on the NASDAQ stock market under the symbol ARVN.

As of January 14, 2025, ARVN stock price declined to $17.22 with 551,773 million shares trading.

ARVN has a beta of 1.32, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.07 to the broad based SPY ETF.

ARVN has a market cap of $1.18 billion. This is considered a Small Cap stock.

Last quarter Arvinas reported $102 million in Revenue and -$.68 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.28.

In the last 3 years, ARVN traded as high as $81.13 and as low as $13.57.

The top ETF exchange traded funds that ARVN belongs to (by Net Assets): VTI, VB, IWM, VXF, VBK.

ARVN has underperformed the market in the last year with a price return of -55.5% while the SPY ETF gained +23.6%. ARVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.1% and -9.4%, respectively, while the SPY returned +0.8% and -1.0%, respectively.

ARVN support price is $17.26 and resistance is $18.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN shares will trade within this expected range on the day.